Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013595" target="_blank" >RIV/00023736:_____/24:00013595 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/23:A2402NIW RIV/00216208:11140/24:10472825 RIV/00216208:11150/24:10472825 RIV/00216208:11160/24:10472825 and 6 more
Result on the web
<a href="https://doi.org/10.1007/s00277-023-05572-0" target="_blank" >https://doi.org/10.1007/s00277-023-05572-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-023-05572-0" target="_blank" >10.1007/s00277-023-05572-0</a>
Alternative languages
Result language
angličtina
Original language name
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Original language description
Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. The results support the growing evidence for Evusheld’s efficacy against severe COVID-19 in patients with hematology malignancies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of hematology
ISSN
0939-5555
e-ISSN
—
Volume of the periodical
103
Issue of the periodical within the volume
3
Country of publishing house
DE - GERMANY
Number of pages
12
Pages from-to
981-992
UT code for WoS article
001125370600001
EID of the result in the Scopus database
2-s2.0-85179728882